{
    "2018-05-09": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Johnson & Johnson Stock Looks Attractive on the Big Dip",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Stock",
                        "Attractive",
                        "Big Dip"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y",
                "features": {
                    "keywords": [
                        "Theravance Biopharma",
                        "Q1",
                        "Loss Narrows",
                        "Sales Up"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biopharma"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-03",
                "original_text": "How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?",
                "features": {
                    "keywords": [
                        "Regeneron",
                        "Eylea",
                        "Kevzara",
                        "Zaltrap",
                        "1Q18"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-27",
                "original_text": "Merck’s Immunology and Cardiovascular Products in 1Q18",
                "features": {
                    "keywords": [
                        "Merck",
                        "Immunology",
                        "Cardiovascular",
                        "1Q18"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for May 10, 2018",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Ex-Dividend",
                        "Date",
                        "Scheduled"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-27",
                "original_text": "A Overview of Merck’s Diabetes Products in 1Q18",
                "features": {
                    "keywords": [
                        "Merck",
                        "Diabetes",
                        "Products",
                        "1Q18"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "See what the IHS Markit Score report has to say about Johnson & Johnson.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "report",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}